Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively
Retatrutide's Phase 2a in MASH/MASLD (Sanyal et al., Nat Med 2024) reported approximately 86% relative reduction in liver fat content at 12 mg/week the strongest hepatic-fat data among the incretin class
We have many repeat customers who self-inject regularly with great success
Why is WFI water important
Changes in glutathione content in liver diseases